Iradimed (NASDAQ:IRMD) Announces Earnings Results

Iradimed (NASDAQ:IRMD) announced its quarterly earnings data on Thursday. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.05), Zacks reports. Iradimed had a return on equity of 23.99% and a net margin of 26.12%. Iradimed updated its Q1 2025 guidance to 0.390-0.430 EPS and its FY 2025 guidance to 1.710-1.810 EPS.

Iradimed Stock Down 7.6 %

Shares of IRMD stock traded down $4.60 during trading hours on Thursday, reaching $55.88. 64,905 shares of the stock traded hands, compared to its average volume of 40,534. The firm has a market capitalization of $708.00 million, a PE ratio of 38.35 and a beta of 0.82. Iradimed has a 1-year low of $40.18 and a 1-year high of $63.29. The business has a fifty day moving average price of $57.16 and a 200 day moving average price of $52.02.

Insider Buying and Selling

In other news, CFO John Glenn sold 2,500 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $54.18, for a total value of $135,450.00. Following the completion of the sale, the chief financial officer now owns 4,383 shares in the company, valued at $237,470.94. This represents a 36.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 37.10% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded Iradimed from a “strong-buy” rating to a “buy” rating in a report on Thursday.

About Iradimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.